Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression

BACKGROUND: Metastatic melanoma has a high mortality rate and suboptimal therapeutic options. Molecular targeting may be beneficial using the rexinoid LGD1069, a retinoid × receptor selective agonist, and thiazolidinediones (TZD), PPARγ selective ligands, as novel treatments. RESULTS: Mouse xenograf...

Descripción completa

Detalles Bibliográficos
Autores principales: Klopper, Joshua P, Sharma, Vibha, Berenz, Andrew, Hays, William R, Loi, Michele, Pugazhenthi, Umarani, Said, Sherif, Haugen, Bryan R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654861/
https://www.ncbi.nlm.nih.gov/pubmed/19267912
http://dx.doi.org/10.1186/1476-4598-8-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654861/
https://www.ncbi.nlm.nih.gov/pubmed/19267912
http://dx.doi.org/10.1186/1476-4598-8-16

Ejemplares similares